LXEO 8-K: SEC filing

Lexeo Therapeutics

Filed with the SEC on · accession 0001193125-26-462015

LXEO filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Lexeo Therapeutics announced positive interim Phase I/II clinical data and regulatory updates for LX2020 in treating PKP2-associated arrhythmogenic cardiomyopathy, alongside its Q3 2026 financial results.

Key details

RegistrantLexeo Therapeutics, Inc.
Chief executive officerR. Nolan Townsend

✦ Ask GOAX AI about this filing — what it means for LXEO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for LXEO?

Click here

Frequently asked questions

What did LXEO file with the SEC on Nov 16, 2026?

LXEO filed a 8-K (SEC filing). Lexeo Therapeutics announced positive interim Phase I/II clinical data and regulatory updates for LX2020 in treating PKP2-associated arrhythmogenic cardiomyopathy, alongside its Q3 2026 financial results.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other LXEO SEC filings

Get alerts when LXEO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days